[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-32616":3,"doc-seo-32616":27},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"file_id":15,"file_url":16,"file_type":17,"file_size":18,"view_count":4,"is_deleted":4,"is_public":19,"is_downloadable":19,"audit_status":19,"page_count":20,"language":21,"language_code":22,"table_of_contents":23,"faqs":24,"seo_title":13,"seo_description":14,"update_tm":25,"read_time":26},32616,16904993612988,"Olivia Brown","https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd",8,"Research & Report","New Epilepsy Therapies in Development","Epilepsy is a common brain disorder marked by spontaneous recurrent seizures, with neuropsychiatric and cognitive comorbidities and elevated mortality. People at risk can often be identified, yet preventive interventions are lacking. In at least 30% of patients, epilepsy remains uncontrolled by current antiseizure medications. Over the past decade, advances in epilepsy genetics, disease models, drug screening technologies, and innovative modalities have produced a pipeline of 200+ therapies. With diagnostic and predictive biomarkers, treatment is shifting toward disease prevention and mechanism-based approaches.","cbCaiqihU4gg1ZG4","https://ap.wps.com/l/cbCaiqihU4gg1ZG4","pdf",2728614,1,27,"English","en","# Introduction\n## Epilepsy: complex disease and treatment\n## Advances in ASM discovery and development\n## Novel epilepsy therapies in development\n## Paradigm shift in epilepsy treatment\n## Conclusions and future directions","[{\"question\":\"Why is epilepsy difficult to prevent or control with current treatment?\",\"answer\":\"Preventive or disease-modifying treatments are not available for those at risk, and at least 30% of patients cannot achieve control with current antiseizure medications.\"},{\"question\":\"What has driven progress in new epilepsy therapies over the last decade?\",\"answer\":\"Breakthroughs in epilepsy genetics, development of novel disease models, improved drug screening technologies, and innovative therapeutic modalities have expanded the preclinical and clinical pipeline.\"},{\"question\":\"How is the approach to epilepsy treatment changing according to the Review?\",\"answer\":\"Care is moving from symptom-only antiseizure drug strategies toward disease prevention, and from broad trial-and-error seizure treatment toward mechanism-based therapies for specific epilepsy syndromes, guided by biomarkers.\"}]",1781738854,68,{"code":4,"msg":28,"data":29},"ok",{"site_id":30,"language":22,"slug":31,"title":13,"keywords":32,"description":14,"schema_data":33,"social_meta":84,"head_meta":86,"extra_data":88,"updated_unix":25},105,"new-epilepsy-therapies-in-development","",{"@graph":34,"@context":83},[35,52,66],{"@type":36,"itemListElement":37},"BreadcrumbList",[38,42,46,49],{"item":39,"name":40,"@type":41,"position":19},"https://docshare.wps.com","Home","ListItem",{"item":43,"name":44,"@type":41,"position":45},"https://docshare.wps.com/document/","Document",2,{"item":47,"name":12,"@type":41,"position":48},"https://docshare.wps.com/document/research-report/",3,{"item":50,"name":13,"@type":41,"position":51},"https://docshare.wps.com/document/new-epilepsy-therapies-in-development/32616/",4,{"url":50,"name":13,"@type":53,"author":54,"headline":13,"publisher":56,"fileFormat":59,"description":14,"dateModified":60,"datePublished":60,"encodingFormat":59,"isAccessibleForFree":61,"interactionStatistic":62},"DigitalDocument",{"name":9,"@type":55},"Person",{"url":39,"name":57,"@type":58},"DocShare","Organization","application/pdf","2026-06-17",true,{"@type":63,"interactionType":64,"userInteractionCount":4},"InteractionCounter",{"@type":65},"ViewAction",{"@type":67,"mainEntity":68},"FAQPage",[69,75,79],{"name":70,"@type":71,"acceptedAnswer":72},"Why is epilepsy difficult to prevent or control with current treatment?","Question",{"text":73,"@type":74},"Preventive or disease-modifying treatments are not available for those at risk, and at least 30% of patients cannot achieve control with current antiseizure medications.","Answer",{"name":76,"@type":71,"acceptedAnswer":77},"What has driven progress in new epilepsy therapies over the last decade?",{"text":78,"@type":74},"Breakthroughs in epilepsy genetics, development of novel disease models, improved drug screening technologies, and innovative therapeutic modalities have expanded the preclinical and clinical pipeline.",{"name":80,"@type":71,"acceptedAnswer":81},"How is the approach to epilepsy treatment changing according to the Review?",{"text":82,"@type":74},"Care is moving from symptom-only antiseizure drug strategies toward disease prevention, and from broad trial-and-error seizure treatment toward mechanism-based therapies for specific epilepsy syndromes, guided by biomarkers.","https://schema.org",{"og:url":50,"og:type":85,"og:title":13,"og:site_name":57,"og:description":14},"article",{"robots":87,"canonical":50},"index,follow",{"doc_id":7,"site_id":30}]